2072873-06-2
Chemical Structure
Sintilimab
Synonym(s): IBI308
- CAS No.: 2072873-06-2
- Formula:N/A
- Molecular Weight:(144.04 kDa)
IUPAC Name: 6-(6-amino-5-methoxypyridin-3-yl)-3-(4-fluorobenzyl)benzo[d]oxazol-2(3H)-one
SMILES: [Sintilimab]
Biological Activity: Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sintilimab | 99.1% | Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Sheridan M Hoy. Sintilimab: First Global Approval Drugs. 2019 Feb;79(3):341-346. [Content Brief]
- [2]. Wang J, et al Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. MAbs. 2019 Nov-Dec;11(8):1443-1451. [Content Brief]
- [3]. Zhang L, et al. Sintilimab: A Promising Anti-Tumor PD-1 Antibody. Front Oncol. 2020 Nov 26;10:594558. [Content Brief]
- [4]. Yan Q, et al. Prebiotics Modulate Gut Microbiota-mediated T-cell Immunity to Enhance the Inhibitory Effect of Sintilimab in Lewis Lung Adenocarcinoma Model Mice. Anticancer Agents Med Chem. 2023;23(17):1966-1973. [Content Brief]
- [5]. Zhang L, et al. Sintilimab for the treatment of non-small cell lung cancer. Biomark Res. 2022 Apr 18;10(1):23. [Content Brief]
Keywords
